Parinda A. Mehta, MD
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- parinda.mehta@cchmc.org
- Board Certified
About
BA: Graduated from Parle College, Mumbai, India, 1988.
MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993.
Residency: Upstate Medical University (UMU) - State University of New York (SUNY), Syracuse, NY, 2002.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005.
Certification: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio.
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Transplantation and Cellular Therapy. 2019; 25:2416-2421.
Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Transplantation and Cellular Therapy. 2018; 24:e11-e19.
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer. 2018; 65:e27034.
Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Journal of Antimicrobial Chemotherapy. 2018; 73:1651-1658.
Abatacept Prevents Severe Acute Graft-Versus-Host Disease Without Increasing Graft Failure Risk in Pediatric Bone Marrow Failure Syndromes. Pediatric Blood and Cancer. 2025; 72:e32085.
LINE-1 Retroelement Activation and Neuroinflammation in Persons With Fanconi Anemia. Pediatric Blood and Cancer. 2025; 72:e32081.
Hepatocyte senescence and persistent liver injury in Fanconi anemia. Haematologica: the hematology journal. 2025; 110:1870-1874.
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Advances. 2025; 9:3469-3478.
Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nature Medicine. 2025; 31:2204-2212.
Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation. Journal of Clinical Oncology. 2025; 43.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey